EGFR and non-small cell lung carcinoma: The results of these studies indicated that a high copy number of plasma T790M or activating EGFR mutations was a useful marker for predicting worse PFS in patients with NSCLC harboring positive EGFR T790M who were treated with osimertinib13,15–17.